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See Editorial, pages 668–670Background & Aims: Fatty liver is a potentially preventable predict fatty liver. Risk assessment based on childhood age, sex,
cause of serious liver diseases. This longitudinal study aimed to BMI, insulin levels, birth weight, TM6SF2 and PNPLA3 was supe-
identify childhood risk factors of fatty liver in adulthood in a
population-based group of Finnish adults.
Methods: Study cohort included 2,042 individuals from the
Cardiovascular Risk in Young Finns Study aged 3–18 years at
baseline in 1980. During the latest follow-up in 2011, the liver
was scanned by ultrasound. In addition to physical and environ-
mental factors related to fatty liver, we examined whether the
genetic risk posed by a single nucleotide polymorphism in the
patatin-like phospholipase domain-containing protein 3 gene
(PNPLA3) (rs738409) strengthens prediction of adult fatty liver.
Results: Independent childhood predictors of adult fatty liver
were small for gestational age, (odds ratio = 1.71, 95% confidence
interval = 1.07–2.72), variant in PNPLA3 (1.63, 1.29–2.07 per one
risk allele), variant in the transmembrane 6 superfamily 2 gene
(TM6SF2) (1.57, 1.08–2.30), BMI (1.30, 1.07–1.59 per standard
deviation) and insulin (1.25, 1.05–1.49 per standard deviation).
Childhood blood pressure, physical activity, C-reactive protein,
smoking, serum lipid levels or parental lifestyle factors did notJournal of Hepatology 20
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protein; OR, odds ratios.rior in predicting fatty liver compared with the approach using
only age, sex, BMI and insulin levels (C statistics, 0.725 vs.
0.749; p = 0.002).
Conclusions: Childhood risk factors on the development of fatty
liver were small for gestational age, high insulin and high BMI.
Prediction of adult fatty liver was enhanced by taking into
account genetic variants in PNPLA3 and TM6SF2 genes.
Lay summary: The increase in pediatric obesity emphasizes the
importance of identification of children and adolescents at high
risk of fatty liver in adulthood. We used data from the longitudi-
nal Cardiovascular Risk in Young Finns Study to examine the
associations of childhood (3–18 years) risk variables with fatty
liver assessed in adulthood at the age of 34–49 years. The find-
ings suggest that a multifactorial approach with both lifestyle
and genetic factors included would improve early identification
of children with a high risk of adult fatty liver.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Fatty liver without excessive alcohol intake is the most common
form of chronic liver disease in Western countries with preva-
lence between 20–30% and 70–90% in the obese and diabetics
[1]. One of the major modifiable risk factors for fatty liver disease
is obesity which often begins in childhood [2,3]. There is no16 vol. 65 j 784–790
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effective cure for advanced fatty liver, and thus the increase in
pediatric obesity emphasizes the importance of identification of
children and adolescents at high risk of fatty liver in adulthood.
Fatty liver is the result of accumulation of triacylglycerol in
the hepatocytes [4–7]. Although evidence that hepatic fat accu-
mulation determines insulin resistance is still lacking in
humans [7], it has been hypothesized that hepatic accumulation
of the diacylglycerols may lead to activation of protein kinase
Ce, resulting in hepatic insulin resistance. Additionally, intracel-
lular compartmentation of diacylglycerols is a critical factor in
determining whether increased hepatic diacylglycerol content
results in hepatic insulin resistance and will likely explain
why some patients with fatty liver are not associated with hep-
atic insulin resistance [8,9]. Besides obesity and diabetes,
recently also genetic factors have been shown to be associated
with fatty liver [7]. Romeo et al. [10] were the first to report
that the rs738409 C>G SNP in the patatin-like phospholipase
domain-containing 3 (PNPLA3) gene, encoding the isoleucine
to methionine variant at protein position 148, was strongly
associated with increased liver fat content [10]. Since then, sev-
eral other pieces of evidence have highlighted the major role of
PNPLA3 in the development and progression of NAFLD [11,12].
Mutated PNPLA3 variant is attached on the surface of lipid dro-
plets reducing triglyceride breakdown leading to lipid retention
in the hepatocyte lipid droplet [7]. In addition to PNPLA3, we
examined other single nucleotide polymorphisms that have
been linked to fatty liver: TM6SF2, GCKR and LYPLAL1 [12].
The low-frequency rs58542926 C>T polymorphism of TM6SF2
encodes the loss-of-function E167K variant, which leads to
reduced secretion of very low-density lipoproteins (VLDL)
resulting in intrahepatic retention of triglycerides and steatosis
[13–17]. The common glucokinase regulator (GCKR) regulates
glucose uptake by hepatocytes [18]. In this study, we used
the rs1260326 encoding for the P446L protein variant. The
P446L variant affects GCKR ability to negatively regulate glucok-
inase in response to fructose-6-phosphate, thereby determining
constitutive activation of hepatic glucose uptake [19]. Single
nucleotide polymorphism in the lysophospholipase-like 1 locus
(LYPLAL1, rs12137855) encodes an enzyme likely involved in
triglycerides catabolism in the liver.
The present study aimed to identify the childhood physical
and environmental predictors of adult fatty liver. We used data
from the longitudinal Cardiovascular Risk in Young Finns Study
to examine the associations of childhood (3–18 years) risk
variables with fatty liver assessed in adulthood at the age of
34–49 years. We also examined whether adding information on
the genetic variants in PNPLA3, TM6SF2, GCKR and LYPLAL1
enhances early identification of children who may be at risk for
adult fatty liver.Materials and methods
Study population
The Cardiovascular Risk in Young Finns Study is an ongoing population-based
follow-up study of atherosclerotic precursors. In 1980, a total of 4,320 Finnish
children in 6 age cohorts (3, 6, 9, 12, 15, and 18 years of age) were invited, and
3,596 (83.2%) participated in the first cross-sectional survey [20]. Participants
were randomly chosen from the national population register. Since then,
follow-ups have been conducted in the whole population in 1983, 1986, 2001,
2007 and 2011. In the latest follow-up in 2011, a total of 2,042 (age, 34–49 years)
participants were reexamined. All participants provided written informed con-Journal of Hepatology 201sent, and the study was approved by Ethics Committee of Hospital District of
Southwest Finland in agreement with the Declaration of Helsinki.
Ultrasound imaging of liver
Ultrasound imaging of the liver was performed for 2,042 study participants using
a validated protocol [21] and Sequoia 512 ultrasound mainframes (Acuson,
Mountain View, CA, USA) with 4.0 MHz adult abdominal transducers. Evaluation
of hepatic steatosis was performed according to liver-to-kidney contrast,
parenchymal brightness, deep beam attenuation and bright vessel walls [22].
According to these criteria the presence of hepatic steatosis was assessed visually
by a one trained ultrasonographer masked to participant’s characteristics.
Clinical characteristics
Height and weight were measured and body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared. Blood pressure was
measured from the brachial artery with a standard mercury sphygmomanometer.
The average of three measurements was used in statistical analysis.
Questionnaires were used to obtain data on smoking, age at menarche, phys-
ical activity, birth weight, birth height, length of gestation, breastfeeding, family
history of coronary heart disease, parental hypertension (self-reported diagnosis
of hypertension in either parent at baseline) and parental occupational status.
Data on birth weight and birth height was verified by well-baby clinic records.
In 1980, 1983 and 1986, questionnaire information on cigarette smoking was col-
lected in participants aged 12 years or older. Individuals who had reported daily
smoking at any age between ages 12 and 18 were defined as smokers. Physical
activity was available in participants aged 9 years or older. The physical activity
index was calculated as previously described (range 5–15) [23]. In 2001, 2007
and 2011 follow-ups, adulthood alcohol consumption data were acquired by
standardized questionnaires. Excess alcohol intake was defined as consuming
P6 alcohol doses all at once at least once a week. By using data collected from
national hospital discharge registries were able to verify that none of the partic-
ipants had viral or autoimmune causes of fatty liver. Furthermore, all results
remained similar after excluding participants with history of cancer (N = 4) and
psychotic disorders (N = 3), who may potentially have medications influencing
liver fat metabolism.
Venous blood samples were drawn after an overnight fast for determination
of serum lipid levels, insulin, and CRP. Serum insulin was measured with
immunoassay [24]. Standard enzymatic methods were used for serum total
cholesterol, triglycerides, and high-density lipoprotein cholesterol [25,26]. Low-
density lipoprotein cholesterol concentration was calculated by the Friedewald
formula in subjects with triglycerides <4.0 mmol/L. Serum high-sensitivity C-
reactive protein (CRP) was analyzed by immunoassay [27].
Genetic analyses
In the present study, we used the SNPs rs738409 near the PNPLA3 gene,
rs58542926 near the TM6SF2 gene, rs12137855 near the gene LYPLAL1 and
rs780094 near the GCKR gene, associated with fatty liver in recently genome-
wide association analyses [10,12,13,15–17,28], as the genetic marker for suscep-
tibility for fatty liver. Genotyping was performed with the custom-built Illumina
BeadChip 670K. Missing genotypes have been imputed to the 1,000 genomes ref-
erence panel and imputed single nucleotide polymorphism have been filtered
based on low call-rate (<0.95), low-information score (<0.4), minor allele fre-
quency <1%, and deviation from Hardy-Weinberg equilibrium (p <5.0  106).
Statistical analyses
The participants were classified into fatty liver and normal liver groups. The risk
allele count for the SNP rs738409 was coded 0/1/2, where 2 denotes a GG and 1 a
GC genotype. Birth weight and height were treated as continuous variables. Pre-
term birth was defined as birth before 37 weeks’ gestation. Small for gestational
age was defined as birth weight below the 10th percentile, appropriate birth
weight for gestational age as birth weight in the 50–90th percentiles and large
for gestational age as birth weight over the 90th percentile. At baseline, the par-
ticipants were classified as smokers if they smoked daily. Parental occupational
status was divided into 3 categories: manual, lower-grade non-manual, and
higher-grade non-manual. Values for triglycerides and CRP were log-
transformed before analyses because of skewed distributions. The distribution
of physical activity index was strongly skewed. Thus, the physical activity index
was divided to quartiles. Alcohol consumption data were calculated in standard6 vol. 65 j 784–790 785
Table 1. Baseline characteristics of participants with and without fatty liver
diagnosis in adulthood (N = 2,042).
Adult fatty liver status in 2011 Normal liver Fatty liver p value
No. 1657 385
Age (yr) 10.7 ± 0.1 12.3 ± 0.3 <0.0001
Male sex (%) 40.0 68.3 <0.0001
BMI (kg/m2) 17.7 ± 0.1 19.0 ± 0.2 <0.0001
z-BMI -0.07 0.14 <0.0001
Systolic blood pressure (mmHg) 112.1 ± 0.3 115.7 ± 0.6 <0.0001
Diastolic blood pressure (mmHg) 68.3 ± 0.3 69.7 ± 0.5 0.01
Total cholesterol (mmol/L) 5.3 ± 0.0 5.1 ± 0.0 0.0006
LDL cholesterol (mmol/L) 3.5 ± 0.0 3.3 ± 0.0 0.0008
HDL cholesterol (mmol/L) 1.6 ± 0.0 1.5 ± 0.0 0.03
Triglycerides (mmol/L) 0.66 ± 0.0 0.70 ± 0.0 0.03
Insulin (mU/L) 9.5 ± 0.1 11.4 ± 0.3 <0.0001
CRP (mg/L) 1.0 ± 0.1 1.0 ± 0.2 0.9
Birth weight (g) 3529 ± 15 3441 ± 32 0.01
Birth height (cm) 50.4 ± 0.1 50.2 ± 0.1 0.2
Large for gestational age (%) 9.4 8.8 0.7
Small for gestational age (%) 9.1 14.8 0.005
Appropriate for gestational age (%) 81.5 76.4 0.06
Preterm birth (%) 3.1 6.9 0.002
Breast-feeding (%)1 85.9 78.8 0.005
Daily smoking (%)a 18.5 23.6 0.03
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doses (12 g pure ethanol) per day by dividing the total number of doses con-
sumed per week (0.33 L doses of beer or cider, 0.12 L doses of wine, and 0.04 L
doses of hard liquor) by 7.
An attrition analysis was performed to determine whether the representa-
tiveness of the baseline sample was maintained in the present cohort; baseline
characteristics were compared between those who participated and those who
did not participate at follow-up.
Logistic regression was used to examine the odds ratios (OR) of adult fatty
liver for a 1-SD increase for each of the continuous childhood variables. The vari-
ables that were significant in age-, sex- and BMI-adjusted analyses were then
added to a multivariable logistic regression model to determine the independent
childhood predictors of adult fatty liver. To examine whether gene variant status
modifies the associations between the predictor variables and fatty liver, we
included predictor variable x gene variant interaction terms in regression models.
The incremental value of adding risk variables to predict adult fatty liver was
examined through the use of alcohol consumption adjusted multivariate logistic
regression models. Additionally, birth weight was selected to the final multivari-
able model and model comparison analysis, and the ORs of birth height, small for
gestational age and preterm birth were assessed in separate models. The ability of
several models to predict fatty liver risk was estimated with alcohol consumption
adjusted C statistics by calculating the area under the receiver-operating charac-
teristic curve, the net reclassification improvement, and the integrated discrimi-
nation index [29]. The net reclassification improvement and integrated
discrimination index were calculated to determine the extent to which incorpo-
ration of birth weight and the genetic variant in PNPLA3 reassigned individuals to
risk categories that more correctly reflected whether the subjects developed fatty
liver in adulthood.
Two-tailed p values less than 0.05 were considered statistically significant. All
statistical analyses were performed with the Statistical Analysis System 9.4 (SAS
Institute Inc., Cary, NC, USA).Physical activity index 8.4 ± 0.1 8.6 ± 0.1 0.3
Mother’s BMI 23.8 ± 0.1 24.7 ± 0.2 <0.0001
Father’s BMI 25.4 ± 0.1 25.8 ± 0.2 0.05
Parental occupational status (%)* 38/43/19 44/42/14 0.03
Parental hypertension prevalence 
(%)
13.6 20.1 0.003
Age at menarche (yr)a 13.1 ± 0.1 12.7 ± 0.1 0.02
Variant in PNPLA3 (CC/CG/GG) (%) 60/36/4 54/38/8 0.003
Variant in TM6SF2 (CC/CT/TT) (%) 90/10/0 82/17/1 0.002
Variant in GCKR (CC/CT/TT) (%) 42/46/12 38/43/19 0.004
Variant in LYPLAL1 (CC/CT/TT) (%) 53/41/6 50/41/9 0.1
BMI, body mass index; CRP, C reactive protein; CHD, coronary heart disease.
Values are least squares means ± standard error for continuous variables and
percentages for categorical variables. 1Breastfed = 1, not breastfed = 0. ⁄Three
categories according to a parental occupation (manual, lower-grade nonmanual,
higher-grade nonmanual). aData available for 12–18 years old participants. z-BMI,
age and sex adjusted body mass index z-score.Results
Baseline characteristics of the study participants (n = 2,042) are
shown in Table 1. The prevalence of adult fatty liver was 19%
(n = 385). To determine whether the representativeness of the
baseline sample was maintained in the present cohort, we
compared the baseline characteristics between those who
participated and those who did not participate at follow-up.
Non-participants were younger (9.9 vs. 10.9 years; p <0.0001,
sex-adjusted analysis of variance) and more often male (54% vs.
45%; p <0.0001, Chi-squared test) than participants. No statisti-
cally significant differences were observed for other baseline
study variables.
Childhood risk factors for adult fatty liver
Age-, sex- and BMI-adjusted ORs and confidence intervals (CI) for
adult fatty liver according to childhood variables are shown in
Table 2. Male sex, preterm birth, small for gestational age,
TM6SF2, PNPLA3, age- and sex-adjusted childhood BMI and insu-
lin levels, low birth weight and low birth height showed signifi-
cant ORs for adult fatty liver.
Multivariable logistic regression models adjusted with adult-
hood long term alcohol consumption were constructed to exam-
ine the independent contributions of childhood risk variables to
the development of the adult fatty liver. Significant variables
from the Table 2 were selected in the models. In a model contain-
ing age, sex, insulin, BMI, birth weight, TM6SF2 and PNPLA3, the
independent predictors of adult fatty liver included male sex,
variant in PNPLA3, variant in TM6SF2, insulin, BMI and birth
weight (Table 3). We also determined in separate multivariable
models the ORs for small for gestational age (OR 1.71, 95% CI
1.07–2.72, p = 0.02), birth height (0.87, 0.75–1.01, p = 0.06) and
preterm birth (2.03, 1.08–3.84, p = 0.03). In the interaction anal-786 Journal of Hepatology 201yses, there were no statistically significant predictor variable x
gene variant interactions. Excluding participants with excess
alcohol intake did not change the results.
Multiple childhood risk factors in predicting adult fatty liver
We studied the ability of multiple childhood risk factors to pre-
dict adult fatty liver with several models (Table 4). Models were
adjusted with long term alcohol consumption. A model that
included age, sex, BMI, insulin and birth weight (model 2) per-
formed better than a model including only age, sex, BMI, and
insulin (model 1) (p = 0.03 model 2 vs. 1). When both PNPLA3
and TM6SF2were included in the model (model 3), the area under
the curve value increased significantly (p = 0.002 when compared
to model 1, and p = 0.05 when compared to model 2). Consistent
improvements were also seen for the net reclassification
improvement and integrated discrimination index between mod-6 vol. 65 j 784–790
Table 2. Age-, sex- and BMI-adjusted odds ratios and 95% confidence intervals
for adult fatty liver for each of the youth variables (N = 2,027).
Variable OR 95% CI p value
Male sex (age- and BMI-adjusted)# 3.33 2.62-4.23 <0.0001
Preterm birth# 2.41 1.37-4.25 0.002
Small for gestational age# 1.75 1.16-2.63 0.008
Variant in TM6SF2* 1.71 1.23-1.37 0.002
Variant in PNPLA3* 1.38 1.12-1.69 0.003
BMI (age- and sex-adjusted)§ 1.34 1.15-1.55 0.0001
Insulin§ 1.29 1.12-1.47 0.0003
Parental hypertension# 1.25 0.89-1.75 0.2
Breast-feeding# 1.29 0.80-2.07 0.3
Variant in LYPLAL1* 1.15 0.95-1.41 0.2
Diastolic blood pressure§ 1.06 0.94-1.21 0.4
Daily smoking a# 1.04 0.78-1.40 0.8
Age (sex- and BMI-adjusted)§ 1.03 1.00-1.07 0.06
Mother´s BMI§ 1.03 1.00-1.06 0.08
Systolic blood pressure§ 1.03 0.89-1.19 0.7
Father´s BMI§ 1.01 0.97-1.06 0.5
CRP§ 1.00 0.96-1.04 1
HDL cholesterol§ 0.98 0.87-1.10 0.7
Triglycerides§ 0.98 0.87-1.10 0.7
Physical activity index|| 0.97 0.79-1.19 0.8
Total cholesterol§ 0.90 0.80-1.02 0.09
LDL cholesterol§ 0.89 0.79-1.01 0.06
Large for gestational age 0.87 0.53-1.41 0.6
Parental occupational status 0.85 0.71-1.02 0.07
Variant in GCKR* 0.83 0.70-1.00 0.05
Birth height§ 0.82 0.72-0.94 0.003
Age at menarche a, b
c
0.80 0.63-1.01 0.06
Birth weight§ 0.77 0.68-0.88 <0.0001
Appropriate for gestational age# 0.76 0.55-1.06 0.1
#||
Values of BMI, systolic and diastolic blood pressure, total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, insulin, CRP, birth weight, birth height
and physical activity index were standardized. OR, odds ratio; CI, confidence
interval. #OR for categorical predictor. ⁄OR per risk allele. §OR for a 1-SD increase.
||OR for a one quartile increase in physical activity index or for parental occu-
pation category. aData only available for 12–18 years old participants. bOnly for
girls. cThree categories according to a parental occupation (manual, lower-grade
non-manual, higher-grade non-manual).
Table 3.Multivariable odds ratios of childhood risk factors for adult fatty liver
(N = 1,456).
Variable OR 95% CI p value
Male sex 3.33 2.41-4.61 <0.0001
Variant in PNPLA3 (per G allele) 1.63 1.29-2.07 <0.0001
Variant in TM6SF2 (per T allele) 1.57 1.08-2.30 0.02
BMI 1.30 1.07-1.59 0.009
Insulin 1.25 1.05-1.49 0.01
Age 1.02 0.98-1.06 0.4
Birth weight 0.81 0.70-0.93 0.004
Values of birth weight, birth height, BMI and insulin were standardized. Age-, sex-
and BMI-adjusted significant variables were selected in the model. OR, odds ratio;
CI, confidence interval. OR for a 1-SD increase. Adjusted with adulthood long term
alcohol consumption.
JOURNAL OF HEPATOLOGYels 1 and 3. Notably, the net reclassification improvement for
model 3 was >28% with respect to the model including only
age, sex, BMI and insulin. Excluding participants with excess alco-
hol intake did not change the results.Discussion
In the present study, we observed that the prediction of fatty
liver in adulthood can be improved significantly by the use of sin-
gle nucleotide polymorphism in the PNPLA3 and TM6SF2 genes
compared with prediction models consisting of only age, sex,
and childhood BMI and insulin levels. Our results also suggest
that the prediction of adult fatty liver is improved by the use of
data on birth weight.
In this study, we were able to take into account several poten-
tial childhood risk factors for adult fatty liver in a large cohort of
children followed up over 30 years. We have recently shown in
this cohort that adulthood determinants of fatty liver are waist
circumference, alanine aminotransferase, BMI, male sex,Journal of Hepatology 201apolipoprotein B, systolic blood pressure, alcohol intake, insulin
and low physical activity index [30]. Insulin and BMI were signif-
icant predictors of fatty liver already in childhood. However, early
life exposure to elevated systolic blood pressure and low physical
activity did not predict adult fatty liver. This emphasizes the role
of childhood BMI as a modifiable risk factor for adult fatty liver.
High childhood insulin level was an independent predictor of
adult fatty liver. A potential explanation is that liver fat accumu-
lation occurs when hyperinsulinemia and insulin resistance lead
to hepatic accumulation of triglycerides. This process usually
results from an imbalance between increased free fatty acid flux
from adipose tissue to the liver, increased caloric intake, and
increased lipogenesis in the liver and the liver’s handling and
export of the extra fat. The free fatty acids are usually either oxi-
dized in the mitochondria or esterified to triglycerides, which in
turn are either packaged as VLDL for export or are used for the
production of lipids [31].
Interestingly, low birth weight was an independent predictor
of adult fatty liver. This is in line with one previous study of 2,003
Finnish adults: a significant association between adulthood liver
fat score (based on five variables: presence of metabolic syn-
drome, presence of type 2 diabetes, fasting serum insulin and
aspartate aminotransferase levels, and aspartate aminotrans-
ferase/alanine aminotransferase ratio) and birth weight was seen
in women [32]. This may be influence of rapid weight catch-up
growth [33,34]. Catch-up growth is recognized as a major risk
factor for later development of insulin-related complications
and chronic diseases like abdominal obesity, type 2 diabetes
and cardiovascular disease [35]. In a longitudinal study of 51
Spanish children, small for gestational age children gained pro-
gressively more body fat and abdominal fat mass than appropri-
ate for gestational age children between ages 2 and 4 years. These
differences occurred despite the small for gestational age chil-
dren having already completed their catch-up growth and weight
gain by age 2 years [36]. On the other hand, low birth weight was
associated with adult fatty liver even when adjusted with child-
hood BMI. This could be explained by the model for the origins of
disease that proposes that nutrition during fetal life, infancy, and
early childhood establish gene expression and thereby perma-
nently set functional capacity, metabolic competence, and
responses to the later environment [37]. Furthermore, it is known
that liver growth may be reduced as part of the adaptive response
to a poor fetal substrate supply [38].
In this study, we used the genetic variants in PNPLA3, TM6SF2,
GCKR and LYPLAL1 genes recognized to being involved in deter-
mining the risk of fatty liver [7,39]. The value of these novel6 vol. 65 j 784–790 787
Table 4. Comparison of models for the prediction of adult fatty liver in 1,456 individuals.
AUC value p value NRI, % p value IDI, % p value H-L p value Model used for comparison
Model 1
Age, sex, BMI, insulin 0.725 2.1 1
Model 2
Model 1 + birth weight 0.736 0.03 12.7 0.06 6.5 0.03 6.8 0.6 1
Model 3
Model 1 + birth weight, 
PNPLA3 and TM6SF2
0.749 0.002 28.6 <0.0001 23.5 <0.0001 11.9 0.2 1
0.05 24.6 0.0003 16.0 <0.0001 2
AUC, area under the curve; CI, confidence interval; NRI, net reclassification improvement; IDI, integrative discrimination index; H-L, Hosmer-Lemeshow x2 statistics.
Adjusted with adulthood long term alcohol consumption.
Research Articlegenetic markers in identifying young individuals at risk for adult
fatty liver disease is unknown. We observed that a combined risk
score based on childhood BMI and insulin levels, birth weight and
the genetic variants in PNPLA3 and TM6SF2 was superior to a
model including only BMI and insulin values in predicting adult
fatty liver. In PNPLA3 gene, rs738409 is a C/G single nucleotide
variation on human chromosome 22. A cytosine to guanine
DNA substitution (rs738409) encodes an isoleucine to methion-
ine loss-of-function substitution at the amino acidic residue
148 of the PNPLA3 protein [40]. Mutated PNPLA3 variant is
attached on the surface of lipid droplets reducing triglyceride
breakdown leading to lipid retention in the hepatocyte lipid dro-
plet [7,41]. Alternatively, it may stimulate the hepatic triglyc-
erides synthesis [42,43]. The variant increases the risk of fatty
liver, but is not associated with increased risk of type 2 diabetes
or cardiovascular disease [44]. However, as the carriers of the
variant allele are at high risk of developing advanced liver dis-
ease, they may be an important target group for lifestyle inter-
vention [45]. The low-frequency rs58542926 polymorphism of
TM6SF2 encodes the loss-of-function E167K variant that has been
linked with fatty liver and lower serum lipoproteins [7]. The
mechanism is related to reduced secretion of VLDL resulting in
intrahepatic retention of triglycerides [7]. Altogether, the present
data suggest that a multifactorial approach if implemented could
improve the identification of children with a high risk of adult
fatty liver. Moreover, these data demonstrate that the prediction
of adult fatty liver was enhanced by taking into account genetic
variants.
Strengths and limitations
We studied a large, randomly selected, and carefully pheno-
typed cohort of young men and women prospectively followed
up for up to 31 years since early childhood. Extensive data were
available on several possible childhood physical, environmental,
and genetic determinants of fatty liver that could be compre-
hensively taken into account in multivariable models. Because
our study cohort was homogeneous ethnic group, the generaliz-
ability of our results is limited to Caucasians. The limitations of
this study include the loss of original participants during the
long term follow-up. We found that non-participants were
younger and more often male in childhood than participants.
Therefore, the rates of adult fatty liver in our cohort might be
an underestimation of the real rates. One limitation of our study
was that we did not have data on liver enzymes measured in
childhood.788 Journal of Hepatology 201Liver biopsy is at present the gold standard for diagnosing
fatty liver, because it is the only way to detect inflammation or
fibrosis [46]. However, it is an invasive procedure with potential
risk of bleeding, and it is not suitable for large-scale population
studies of fatty liver [47,48]. Ultrasound imaging has also its lim-
itations: while the test shows high specificity, it has low sensitiv-
ity [49]. It has been estimated that conventional ultrasound
imaging can only detect steatosis when more than 30% of the
liver is affected [50]. However, a large meta-analysis [51] con-
cluded that ultrasonography allows for reliable and accurate
detection of moderate-severe fatty liver, compared to histology.
Liver ultrasound is an operator-dependent modality with varying
results between operators. In the meta-analysis by Hernaez et al.,
the range of kappa values for intra-rater evaluation was 0.54–
0.92 [51]. In our study, all ultrasound images were graded by
one trained operator who was masked for participant’s clinical
characteristics. Because ultrasound imaging is non-invasive,
widely accessible, and cost-effective, it is likely a reasonable
choice for population-based studies into the etiogenesis of fatty
liver [51].
Conclusions
We found that low birth weight, the SNP rs738409 in the PNPLA3
gene, the SNP rs58542926 in the TM6SF2 gene and insulin and
BMI levels measured in childhood were independently related
to fatty liver detected 31 years later in adulthood. Including infor-
mation on birth weight, rs738409 and rs58542926 in addition to
childhood BMI and insulin levels significantly improved the abil-
ity of the statistical model to predict adult fatty liver. Therefore,
the present findings suggest that a multifactorial approach if
implemented would improve early identification of children with
a high risk of adult fatty liver.Financial support
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